NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  News | News By Subject | News by Disease News By Date | Search News
   

Wake Pharm US Announces Appointment of Jeffrey A. Niezgoda, M.D. to the Board of Medical Advisors
6/29/2009

ELK GROVE VILLAGE, Ill., June 29 /PRNewswire/ -- Wake Pharm US announced today the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Director of the Company's Medical Advisory Board.

Dr. Jeffrey Niezgoda is a leading wound management physician and the Medical Director of the Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of Hyperbaric & Wound Care Associates, a medical specialty group serving Southeastern Wisconsin and Northern Illinois, and as the President of the American College of Hyperbaric Medicine.

Dr. Niezgoda stated, "I am very pleased to accept the position of Director of the Advisory Board and to have the opportunity to contribute to the company's clinical mission. My clinical experience with Wound Be Gone(R) has produced impressive results with improved wound healing trajectories. Wound Be Gone(R) is placing wound care into the hands of people who might otherwise suffer or whose wound problems might escalate to need for expensive invasive medical intervention."

Ludek Lolek, President & CEO of Wake Pharm US commented, "Dr. Niezgoda has been an invaluable resource to the Wound Be Gone(R) brand. His clinical insight and experience has been a tremendous asset to our development team. As Director of our Medical Advisory Board, Dr. Niezgoda will help us to accelerate the growth of our product line."

Wound-Be-Gone(R) is a novel hydrophilic gel that has been shown to demonstrate enhanced wound healing in varied clinical settings with both acute and chronic wounds. The mechanism of action appears to be related to a decrease in inflammatory mediators due to the active scavenging of oxygen free radicals. Visit www.woundbegone.com for more details.

About Wake Pharm US:

Wake Pharm US is an innovative and international company with its own manufacturing facility located in the Czech Republic (European Union). Wake Pharm US specializes in developing, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharm US, please visit our website at www.wakepharmus.com.

CONTACT: Damian Styga of Wake Pharm US, +1-224-366-3900,
dstyga@wakepharmus.com

Web site: http://www.wakepharmus.com/



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES